Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

ABSTRACT:

Background

Inter-patient pharmacokinetic variability can lead to suboptimal drug exposure, and therefore might impact the efficacy of sorafenib. This study reports long-term pharmacokinetic monitoring of patients treated with sorafenib and a retrospective pharmacodynamic/pharmacokinetic analysis in melanoma patients.

Patients and methods

Heavily pretreated patients with stage IV melanoma were started on sorafenib 400 mg twice daily (bid). In the absence of limiting toxicity, dose escalation of 200 mg bid levels was done every 2 weeks. Plasma sorafenib measurement was performed at each visit, allowing a retrospective pharmacodynamic/pharmacokinetic analysis for safety and efficacy.

Results

In all, 19 of 30 patients underwent dose escalation over 400 mg bid, and 28 were

SUBMITTER: Pecuchet N 

PROVIDER: S-EPMC3405224 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature